search
Back to results

Bone Microarchitecture in Men With Hemophilia (HEMOS)

Primary Purpose

Severe Hemophilia A, Osteoporosis

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
HR-pQCT
Blood sample
Dual energy X-ray absorptiometry
medical data collection
Sponsored by
Hospices Civils de Lyon
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Severe Hemophilia A focused on measuring Hemophilia, osteoporosis, bone microarchitecture, bone remodeling

Eligibility Criteria

20 Years - 60 Years (Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

Patients:

  • Men aged 20 to 60 years
  • Severe hemophilia A or B (FVIII or FIX<1%)
  • Regular followed up in Lyon Hemophilia Center
  • Ability to give free and informed consent
  • Person capable of actively participating in radiological examinations

Healthy Mens:

  • Aged 20 to 60 years

Exclusion Criteria:

  • Women
  • Not covered by health system
  • Vulnerable (adults unable to consent, protected under guardianship, prisoner)
  • Any blood coagulation abnormality other than severe hemophilia A or B
  • Having one of the following treatments against osteoporosis of more than 6 months : bisphosphonates, denosumab, teriparatide
  • With a chronical disease having a high impact on bone structure and no related to hemophilia disease, such as Cushing or Crohn diseases.

Sites / Locations

  • Hôpital Cardio-Vasculaire et PneumologiqueRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

severe hemophilia A or B patients

healthy men

Arm Description

30 patients with severe hemophilia A or B (Factor (F)VIII or Factor IX (FIX)≤ 1%) aged 20 to 60 years will be included in this study.

Data of healthy men, matching in age- height-weight-ethnicity and smoking-matched with patient will be collected. These data are already available at the "Institut national de la santé et de la recherche médicale" (INSERM) research unit associated.

Outcomes

Primary Outcome Measures

number of trabecular at distal tibia
The number of trabecular at distal tibia will be performed and compared to the values available for the healthy control group
number of trabecular at distal radius
The number of trabecular at distal radius will be performed and compared to the values available for the healthy control group

Secondary Outcome Measures

Sera bone remodeling biomarkers
This biomarkers will be performed: PINP (ng/ml) CTX-1 (ng/ml) Periostin (ng/ml)
reflection of bone strength
Micro-Finite Element Analysis (µFEA) reflection of bone strength will be performed and compared to the values available for the healthy control group
Trabecular Bone Score (TBS)
Trabecular Bone Score (TBS) will be performed and compared to the values available for the healthy control group The trabecular bone score is a measure of bone texture correlated with bone microarchitecture and a marker for the risk of osteoporosis

Full Information

First Posted
October 6, 2021
Last Updated
September 6, 2023
Sponsor
Hospices Civils de Lyon
search

1. Study Identification

Unique Protocol Identification Number
NCT05127681
Brief Title
Bone Microarchitecture in Men With Hemophilia
Acronym
HEMOS
Official Title
Bone Microarchitecture in Men With Hemophilia
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 1, 2023 (Actual)
Primary Completion Date
January 11, 2025 (Anticipated)
Study Completion Date
January 11, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospices Civils de Lyon

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Hemophilia A and B are hereditary sex-linked deficiencies of coagulation factors VIII and IX characterized by bleeding. Their modern therapy increases life expectancy and risk of age-related diseases, e.g., osteoporosis. Hemophilia-specific risk factors impair formation of peak bone mass and accelerate bone loss. Fractures are more frequent in hemophilic men vs. age-matched men and induce bleeding which is aggravated by manipulations and surgical intervention. The hypothesis of this study is that hemophilic men have poor bone microarchitecture (assessed by High-resolution peripheral quantitative computed tomography (HR-pQCT)) related to an imbalance between bone formation and resorption (assessed by bone turnover markers (BTM) and bone biomarkers). The study aims to assess the difference in low trabecular number (Tb.N) at the distal radius between hemophilic men (cases) and age- height-weight-ethnicity and smoking-matched healthy men (controls). Correlation between BTM and Tb.N will be also studied. Biologic markers of bone remodeling (C-terminal telopeptide of type I collagen (PINP), N-terminal propeptide of type I procollagen (CTX-I), periostin) will be studied.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Severe Hemophilia A, Osteoporosis
Keywords
Hemophilia, osteoporosis, bone microarchitecture, bone remodeling

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
severe hemophilia A or B patients
Arm Type
Experimental
Arm Description
30 patients with severe hemophilia A or B (Factor (F)VIII or Factor IX (FIX)≤ 1%) aged 20 to 60 years will be included in this study.
Arm Title
healthy men
Arm Type
Other
Arm Description
Data of healthy men, matching in age- height-weight-ethnicity and smoking-matched with patient will be collected. These data are already available at the "Institut national de la santé et de la recherche médicale" (INSERM) research unit associated.
Intervention Type
Radiation
Intervention Name(s)
HR-pQCT
Intervention Description
Patients will have a unique HR-pQCT scanner imaging to study their bone microarchitecture
Intervention Type
Biological
Intervention Name(s)
Blood sample
Intervention Description
Patients will have a unique blood sampling of 10 mL for the measurements of sera PINP, CTX-I, periostin levels
Intervention Type
Radiation
Intervention Name(s)
Dual energy X-ray absorptiometry
Intervention Description
A dual energy X-ray absorptiometry scan of lumbar spine, hip, distal radius and whole body, body composition, lateral spine will be performed.
Intervention Type
Other
Intervention Name(s)
medical data collection
Intervention Description
Data of healthy men is already available
Primary Outcome Measure Information:
Title
number of trabecular at distal tibia
Description
The number of trabecular at distal tibia will be performed and compared to the values available for the healthy control group
Time Frame
3 months following the inclusion
Title
number of trabecular at distal radius
Description
The number of trabecular at distal radius will be performed and compared to the values available for the healthy control group
Time Frame
3 months following the inclusion
Secondary Outcome Measure Information:
Title
Sera bone remodeling biomarkers
Description
This biomarkers will be performed: PINP (ng/ml) CTX-1 (ng/ml) Periostin (ng/ml)
Time Frame
3 months following the inclusion
Title
reflection of bone strength
Description
Micro-Finite Element Analysis (µFEA) reflection of bone strength will be performed and compared to the values available for the healthy control group
Time Frame
3 months following the inclusion
Title
Trabecular Bone Score (TBS)
Description
Trabecular Bone Score (TBS) will be performed and compared to the values available for the healthy control group The trabecular bone score is a measure of bone texture correlated with bone microarchitecture and a marker for the risk of osteoporosis
Time Frame
3 months following the inclusion

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients: Men aged 20 to 60 years Severe hemophilia A or B (FVIII or FIX<1%) Regular followed up in Lyon Hemophilia Center Ability to give free and informed consent Person capable of actively participating in radiological examinations Healthy Mens: Aged 20 to 60 years Exclusion Criteria: Women Not covered by health system Vulnerable (adults unable to consent, protected under guardianship, prisoner) Any blood coagulation abnormality other than severe hemophilia A or B Having one of the following treatments against osteoporosis of more than 6 months : bisphosphonates, denosumab, teriparatide With a chronical disease having a high impact on bone structure and no related to hemophilia disease, such as Cushing or Crohn diseases.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dargaud Yesim, PU,PH
Phone
0472118810
Ext
+33
Email
gamze.dargaud@chu-lyon.fr
Facility Information:
Facility Name
Hôpital Cardio-Vasculaire et Pneumologique
City
Bron
ZIP/Postal Code
69677
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
DARGAUD Yesim, PU,PH
Phone
0472118810
Ext
+33
Email
gamze.dargaud@chu-lyon.fr
First Name & Middle Initial & Last Name & Degree
DARGAUD Yesim, PU,PH

12. IPD Sharing Statement

Learn more about this trial

Bone Microarchitecture in Men With Hemophilia

We'll reach out to this number within 24 hrs